
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES
EXCHANGE ACT OF 1934**

For the month of May 2026

Commission File Number: **001-37384**

Lakefront Biotherapeutics
(Translation of registrant's name into English)

Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F Form 40-F

The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333-218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).

On May 26, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

[Exhibit 99.1. Press release dated May 26, 2026](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Lakefront Biotherapeutics

(Registrant)

Date: May 27, 2026

/s/ Annelies Denecker

Annelies Denecker
Company Secretary

				instrument is exercised		
Merrill Lynch International	Right to Recall			143,430	0.22%	physical
Merrill Lynch International	Rights of Use			6,054	0.01%	physical
BofA Securities, Inc.	Right to Use			5,068,385	7.69%	physical
Merrill Lynch International	Call Option	19/06/2026		100,000	0.15%	physical
Bank of America, National Association	Swaps	15/10/2027		48,575	0.07%	cash
Bank of America, National Association	Swaps	15/06/2027		14,311	0.02%	cash
Merrill Lynch International	Swaps	15/01/2027		10,363	0.02%	cash
Merrill Lynch International	Swaps	30/04/2027		44,893	0.07%	cash
Merrill Lynch International	Swaps	30/06/2027		819	0.00%	cash
Merrill Lynch International	Swaps	15/06/2027		14,311	0.02%	cash
Merrill Lynch International	Swaps	10/05/2027		424	0.00%	cash
Merrill Lynch International	Swaps	09/09/2027		256	0.00%	cash
Merrill Lynch International	Swaps	21/06/2027		273	0.00%	cash
Merrill Lynch International	Swaps	15/10/2027		48,575	0.07%	cash
Merrill Lynch International	Swaps	30/06/2026		453	0.00%	cash
Merrill Lynch International	Swaps	29/01/2027		1,680	0.00%	cash
	TOTAL			5,502,802	8.35%	

TOTAL (A&B)	# of voting rights	% of voting rights
	6,126,236	9.30%

The chain of control has been described at the end of the notification (section 11) and can be found [here](#).

About Lakefront® Biotherapeutics

Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas. For more information, visit <https://www.lakefrontbio.com> or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics: Investor Relations

Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com

¹ Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions, as amended from time to time.